Table 2.
Patient and Treatment Characteristics for Patients Undergoing Surgery, EBRT or SBRT for Stage I SCLC
| Characteristic | All Patients (n = 2678) | Surgery (n = 943) | EBRT (n = 1595) | SBRT (n = 140) |
|---|---|---|---|---|
| Mean Age, Years | 68 | 68 | 68 | 73 |
| Sex | ||||
| Male | 1157 (43.2) | 393 (41.7) | 699 (43.8) | 65 (46.4) |
| Female | 1521 (56.8) | 550 (58.3) | 896 (56.2) | 75 (53.6) |
| Race | ||||
| Caucasian | 2413 (90.1) | 864 (91.6) | 1424 (89.3) | 125 (89.3) |
| African American | 195 (7.3) | 57 (6.0) | 128 (8.0) | 10(7.1) |
| Other or not identified | 70 (2.6) | 22 (2.3) | 43 (2.7) | 5 (3.6) |
| Charlson—Deyo Score | ||||
| 0 | 1452 (54.2) | 407 (43.2) | 978 (61.3) | 67 (47.9) |
| 1 | 855 (31.9) | 381 (40.4) | 426 (26.7) | 48 (34.3) |
| 2+ | 371 (13.9) | 155 (16.4) | 191 (12.0) | 25 (17.9) |
| T Stage | ||||
| 1 | 1602 (59.8) | 736 (78.0) | 752 (47.1) | 114 (81.4) |
| 2 | 1076 (40.2) | 207 (22.0) | 843 (52.9) | 26 (18.6) |
| Facility Type | ||||
| Community cancer program | 359 (13.4) | 93 (9.9) | 260 (16.3) | 6 (4.3) |
| Comprehensive community cancer program | 1300 (48.5) | 432 (45.8) | 814 (51.0) | 54 (38.6) |
| Academic/research program | 743 (27.7) | 324 (34.4) | 366 (22.9) | 53 (37.9) |
| Other/not recorded | 276 (10.3) | 94 (9.9) | 155 (9.7) | 27 (19.3) |
| Chemotherapy | ||||
| Yes | 2064 (77.1) | 505 (53.6) | 1488 (93.3) | 71 (50.7) |
| No | 569 (21.2) | 401 (42.5) | 101 (6.3) | 67 (47.9) |
| Unknown | 45 (1.7) | 37 (3.9) | 6 (0.4) | 2(1.4) |
| Chemotherapy Sequencing | ||||
| Neoadjuvant | 991 (37.0) | 12 (1.3) | 951 (59.6) | 28 (20.0) |
| Concurrent | 478 (17.8) | NA | 469 (29.4) | 9 (6.4) |
| Adjuvant | 478 (17.8) | 436 (46.2) | 12 (0.8) | 30 (21.4) |
| Other/timing not reported | 117 (4.4) | 57 (6.0) | 56 (3.5) | 4 (2.9) |
Data are presented as n (%) except where otherwise noted.
Abbreviation: SCLC = small-cell lung cancer.